August 3, 2022. The Court in the Puma Biotechnology securities matter (Central District of California) approved a class action settlement in the amount of $54.2 million. The settlement followed a 2019 federal jury trial that resulted in the jury finding Puma Biotechnology guilty of securities fraud. Plaintiffs alleged that Puma Biotechnology made false and misleading statements regarding the results of the ExteNET trial and the efficacy and safety of the neratinib drug. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports on market efficiency, loss causation and damages, and provided testimony at trial.


Read more on this case at Stanford Securities Class Action Clearinghouse